Shopping Cart
Remove All
Your shopping cart is currently empty
Tilogotamab (GEN-1029) is an agonistic hexameric complex targeting two independent epitopes on DR5, used for studying multiple myeloma (MM).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | In Stock | In Stock | |
| 5 mg | $568 | - | In Stock | |
| 10 mg | $910 | - | In Stock | |
| 25 mg | $1,370 | - | In Stock |
| Description | Tilogotamab (GEN-1029) is an agonistic hexameric complex targeting two independent epitopes on DR5, used for studying multiple myeloma (MM). |
| In vitro | Tilogotamab (20 μg/mL,24h) induced strong cytotoxicity in primary multiple myeloma (MM) cells. [1] |
| In vivo | Tilogotamab at a concentration of 20 μg/mL for 24 hours exhibits potent cytotoxicity against primary MM cells [1]. Tilogotamab is a mixture of two non-competitive DR5-specific monoclonal immunoglobulin G1 (IgG1) antibodies, each featuring an E430G mutation in the Fc domain. This mutation enhances Fc-Fc interactions, leading to antibody hexamerization and subsequent FcγR-independent clustering of DR5 molecules [1]. |
| Synonyms | Hx-DR5-01/05, HexaBody-DR5/DR5, GEN-1029, GEN1029 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2109731-10-2 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.